NCT02834390 2025-03-05
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
Clinical Trials
11 trialsNCT02668653 2024-08-06
QuANTUM-First
Daiichi Sankyo
Phase 3 Completed
NCT03723681 2022-07-29
Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT02039726 2021-02-24
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
Daiichi Sankyo
Phase 3 Completed
NCT00462761 2020-05-11
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Daiichi Sankyo
Phase 1 Completed
NCT02984995 2020-02-17
Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
Daiichi Sankyo
Phase 2 Completed
NCT01565668 2019-12-27
Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Daiichi Sankyo
Phase 2 Completed
NCT00989261 2019-12-11
ACE
Daiichi Sankyo
Phase 2 Completed
NCT01049893 2019-02-12
Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Completed
NCT01390337 2019-02-12
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT01468467 2019-02-12
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed